Trial Profile

A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination With Venetoclax in Adult Patients With Acute Myeloid Leukemia

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cedazuridine/decitabine (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Pharmacokinetics; Therapeutic Use
Acronyms ASCERTAIN-V
Sponsors Astex Pharmaceuticals; Taiho Oncology

Most Recent Events

08 Dec 2025 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.
23 May 2025 Results presented in the Taiho Pharmaceutical Media Release.
22 May 2025 According to a Taiho Pharmaceutical media release, results form this trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 through June 3 at McCormick Place in Chicago.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com